Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find ...

Treatment with a BRAF inhibitor of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation has an estimated 5-year survival rate of 34%, with 19% being progression free. To improve ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

PM CDT at the ASCO Annual MeetingMIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ...

在结直肠癌（CRC）治疗中，BRAFV600E突变患者预后差，BRAF 和 EGFR 抑制剂联合疗法虽有应用，但存在耐药问题。研究人员开展了关于 LSD1 抑制对 BRAF 突变型 CRC 靶向治疗影响的研究，发现抑制 LSD1 可阻断细胞谱系可塑性，有望改善患者治疗反应。 在癌症治疗的漫长 ...

Search for other works by this author on: ...

Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge.

pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who ...

AACR's achievement awards and lectureships recognize innovation in basic, translational, clinical, and epidemiological cancer research.

Prophecy against Eli fulfilled (1 Kin. 2:26-27); Abiathar banished from the priesthood; Solomon's instructions concerning Joab and Shimei (2:28-46; see 2:5-9); Solomon's marriage to Pharaoh's daughter ...